Antiinflammatory Therapy with Canakinumab for Atherosclerotic DiseasePaul M. Ridker, Robert J. Glynn, Tom Thurén et al.|New England Journal of Medicine|2017Cited by 9.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trialPaul M. Ridker, Hakan Kültürsay, Petar Otašević et al.|The Lancet|2017Cited by 1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trialPaul M. Ridker, Patrick Commerford, Jean MacFadyen et al.|The Lancet|2017Cited by 881
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary SyndromesPierluigi Tricoci, Kenneth W. Mahaffey, Zhen Huang et al.|New England Journal of Medicine|2011Cited by 753
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary InterventionKenichi Tsujita, Hisao Ogawa, Seigo Sugiyama et al.|Journal of the American College of Cardiology|2015Cited by 449